Diseases of programmed cell death

Stable Identifier
R-HSA-9645723
Type
Pathway
Species
Homo sapiens
Locations in the PathwayBrowser
General
SVG |   | PPTX  | SBGN
Click the image above or here to open this pathway in the Pathway Browser

Programmed cell death is frequently impaired in cancer and is thought to significantly contribute to resistance to chemotherapy. Mutations and perturbations in expression of different proteins involved in programmed cell death, such as TP53 (p53), BH3-only family proteins, caspases and their regulators enable malignant cells to evade apoptosis (Ghavami et al. 2009, Chao et al. 2011, Wong 2011, Fernald and Kurokawa 2013, Ichim and Tait 2016).

Literature References
PubMed ID Title Journal Year
21943236 Apoptosis in cancer: from pathogenesis to treatment

Wong, RS

J. Exp. Clin. Cancer Res. 2011
19505876 Apoptosis and cancer: mutations within caspase genes

Ghavami, S, Hashemi, M, Ande, SR, Yeganeh, B, Xiao, W, Eshraghi, M, Bus, CJ, Kadkhoda, K, Wiechec, E, Halayko, AJ, Los, M

J. Med. Genet. 2009
22158022 Programmed cell removal: a new obstacle in the road to developing cancer

Chao, MP, Majeti, R, Weissman, IL

Nat. Rev. Cancer 2011
23958396 Evading apoptosis in cancer

Fernald, K, Kurokawa, M

Trends Cell Biol. 2013
27364482 A fate worse than death: apoptosis as an oncogenic process

Ichim, G, Tait, SW

Nat. Rev. Cancer 2016
Participants
Participates
as an event of
Disease
Name Identifier Synonyms
cancer DOID:162 malignant tumor, malignant neoplasm, primary cancer
neurodegenerative disease DOID:1289 degenerative disease, Neurodegenerative disease
Created
Cite Us!